Effect of PP-01 on Cannabis Withdrawal Syndrome

Cannabis Withdrawal Clinical Trial

Official title: A Phase 2, Multicenter, Randomized, Double-Blind, Multiple-Dose, Placebo Controlled Clinical Trial of Two Doses of PP-01 for the Mitigation of Cannabis Withdrawal Symptoms

Status Completed

Clinical Trial Summary

This study will be a randomized, double-blind, placebo-controlled, multicenter trial conducted to evaluate whether PP-01 mitigates the withdrawal symptoms associated with discontinuing cannabis in participants with moderate to severe Cannabis Use Disorder (CUD). The study will enroll approximately 225 participants with moderate to severe CUD and will include 5 arms, including a placebo arm, to help assess the incidence and severity of withdrawal symptoms in heavy long-term users of cannabis. Participants receive study medication for 34 days and participate in 11 visits (7 at a clinic and 4 telemedicine).

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Cannabis Withdrawal
• Marijuana Abuse

• NCT number: NCT05494437
• Study type: Interventional
• Source: PleoPharma, Inc.
• Status: Completed
• Phase: Phase 2
• Start date: October 27, 2022
• Completion date: August 21, 2023